< PreviousSCIENTIFIC PROGRAMME70 Saturday, 23 April 2022 OS02211:00 - 12:00Hall G 1-Hour Oral Session Rapid diagnostic tools inform prudent antibiotic use ChairsGiulia De Angelis (Rome, Italy) Po-Ren Hsueh (Taichung, Taiwan, China) O0098Promoting prudent antibiotic use in nursing homes: a Norwegian nationwide antibiotic quality improvement programme P.E. Akselsen* (Bergen, Norway), N.J. Harbin, R.D. Eig, A. Alkayssi, J.B. Haug, M. Romøren, H.S. Blix, K. Enoksen, S. Høye, M. Lindbæk O0099Procalcitonin-guided antibiotics for lower respiratory tract infections in primary care: can we do better? J. Knüsli* (Lausanne, Switzerland), L. Lhopitallier, A. Kronenberg, J.Y. Meuwly, O. Opota, M.A. Perrenoud, M.A. Page, K. Kain, V. D’acremont, N. Senn, Y. Mueller, I. Locatelli, N. Boillat-Blanco O0100Commercial test that distinguishes between viral and bacterial infection in sepsis patients S. Motov* (Staten Island, United States), C.A. Arias, R.G. Bachur, S. Esposito, S. Halabi, S.L. Kaplan, A. Klein, R. Rothman, L.M. Ryan, S. Shiber, T. Tenenbaum, A. Weissman O0101Early empirical antibiotic therapy modification in sepsis using beta-lacta test directly on blood cultures A. Mizrahi* (Paris, France), F. Jaureguy, H. Petit, G. Péan De Ponfilly, E. Carbonnelle, A. Le Monnier, J.R. Zahar, B. Pilmis O0102Short versus extended treatment with a carbapenem in haematology patients with high- risk fever of unknown origin during neutropenia: an open-label, multi-centre, randomised clinical trial N. De Jonge* (Amsterdam, Netherlands), J. Sikkens, S. Zweegman, A. Beeker, P. Ypma, A.H. Herbers, W. Vasmel, A.M. De Kreuk, J.L.L.M. Coenen, B. Lissenberg-Witte, M.H.H. Kramer, M. Agtmael, J.J.W.M. Janssen OS02311:00 - 12:00Hall H 1-Hour Oral Session New Insights about PK/PD of antifungal agents ChairsJoseph Meletiadis (Athens, Greece) Birgit Willinger (Vienna, Austria) O0103Serum isavuconazole concentrations in immunocompromised hosts with invasive mould infections: an Asian perspective, implications for dosing and therapeutic drug monitoring F.Z.Y. Chan* (Singapore, Singapore), P.Y. Zhou, W.T. Leow, F.I. Zulkifli, K.K.K. Goh, P.Z.B. Cherng, Y.E. Teh, B.H. Tan, G.C. Wong, T.P. Lim, L.H.A. Kwa, S.J. Chung O0104In vitro comparative pharmacodynamics of isavuconazole against Aspergillus fumigatus, A. terreus and A. flavus in an in vitro pharmacokinetic/pharmacodynamic model P. Paranos* (Athens, Greece), M. Siopi, H. Van Der Lee, J. B. Buil, P. Verweij, S. Pournaras, J. Meletiadis O0105Antifungal drug penetration in infected human body fluids and tissues A. Cancela Costa* (Lausanne, Switzerland), E. Glampedakis, A. Kritikos, F. Grass, E. Uldry, C. Delabays, J. Perentes, J.L. Pagani, B. Guery, J.A. Da Silva Pereira Clara, L.A. Decosterd, F. Lamoth O0106Venetoclax and ibrutinib pharmacokinetics unaltered when co-administered with rezafungin T. Sandison* (San Diego, United States), S. Flanagan, V. Ong O0107Posaconazole bioavailability following administration of the solid oral tabletis reduced in haematological patients with severe intestinal mucositis A. Jansen* (Nijmegen, Netherlands), E. Muilwijk, W. Van Der Velden, J. Maertens, R. Aerts, A. Colbers, D. Burger, P. Verweij, R. Ter Heine, N. Blijlevens, R. Brüggemann OS02411:00 - 12:00Hall M 1-Hour Oral Session COVID-19 in special populations ChairsNicolas Müller (Zurich, Switzerland) Cristiana Oprea (Bucharest, Romania) O0108Impact of COVID-19 on functional status in French oldest populations: COVID-OLD multi-centre study G. Gavazzi* (Grenoble, France), C. Arlaud, T. Fraisse, J.P. Vittoz, M. Paccalin, J.P. Lanoix, L. Bernard, P. Carraux-Paz, A. Putot, C. Roubaud, S. Diamantis, N. Baclet, E. Forestier O0109COVID-19 in pregnant women in a tertiary referral centre: preliminary outcomes of a prospective study I. Garcia-Ruiz* (Barcelona, Spain), B. Serrano, A. Suy, E. Sulleiro, F.J. Barranco, P. Garcia-Aguilar, J. Gil, E. Carreras, N. Fernandez-Hidalgo O0110Association of long-term use of immunosuppressant drugs with severity of COVID-19 in Stockholm: a cohort study A. Requena-Mendez* (Stockholm, Sweden), R. Brodin, S.D. Van Der Werff, P. Hedberg, A. Färnert, P. Naucler, P. Bergman O0111COVID-19 in renal transplant recipients: experience of 243 patients from a single-centre in Pakistan A. Nasim* (Karachi, Pakistan), S. DodaniFINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202371 Saturday, 23 April 2022 O0112Predictors of clinical evolution of SARS-CoV-2 infection in haematological patients: a systematic review and meta-analysis A.M. Azzini* (Verona, Italy), E. Razzaboni, M.E. De Rui, M. Guedes, A. Gorska, Z.R. Palacios- Baena, G. Caponcello, F. Arbizzani, B. Tazza, C. Visco, M. Giannella, M. Krampera, J. Rodriguez-Bano, E. Tacconelli, E. Carrara OF02511:00 - 12:00Hall L 1-Hour Mini-oral Flash Session Innovative preclinical PK/PD studies ChairsSandrine Marchand (Poitiers, France) Jason Roberts (Brisbane, Australia) O0113Characterisation of in vivo acquired ceftolozane- tazobactam resistance in Pseudomonas aeruginosa using a PK/PD modelling approach L. Deroche* (Poitiers, France), L. Darnaud, M. Thiry, A. Chauzy, L. Prouvensier, L. Laval, S. Marchand, M.C. Ploy, B. François, W. Couet, O. Barraud, J. Buyck O0114Pharmacodynamics of meropenem and tobramycin for neonatal meningoencephalitis: a novel approaches to facilitate the development of new agents to address the challenge of antimicrobial resistance N. Farrington* (Liverpool, United Kingdom), L. Mcentee, A. Johnson, J. Unsworth, A. Jimenez- Valverde, C. Darlow, R.G. Greenberg, C.P. Hornik, J. Schwartz, S. Das, W. Hope O0115In vivo pharmacodynamic evaluation of meropenem-nacubactam in murine thigh and lung infection models against Klebsiella pneumoniae(KPN) containing OXA-48-like enzymes A. Lepak* (Madison, United States), B. Vanscoy, H. Sader, P. Ambrose, D. Andes O0116Temocillin activity against KPC-2-producing Klebsiella pneumoniae strains in a hollow-fibre infection model J.L. Rodríguez-Ochoa* (Seville, Spain), P. Pérez-Palacios, M. Ortiz-Padilla, A. Velazquez- Escudero, V. Merino-Bohorquez, J. Rodríguez- Baño, J.M. Rodríguez-Martinez, L. López-Cerero, F. Docobo-Pérez, Á. Pascual-Hernández O0117Synergistic penicillin-binding protein (PBP) occupancy patterns against Klebsiella pneumoniae (KP) characterised via confocal microscopy, flow cytometry, and quantitative systems pharmacology E. Shin* (Orlando, United States), A.R.M. Sayed, Y. Lang, J. Zhou, J.L. Oyer, B. Moya, A.A.S. Elsayed, D.S. Sutaria, N.R. Shah, C. Werkman, R.H. Jimenez- Nieves, K.C. Cadet, X. Tao, Y. Jiao, A.J. Copik, R.A. Bonomo, H.P. Schweizer, R.E. Lee, J.D. Boyce, A. Louie, B.T. Tsuji, G.L. Drusano, J.B. Bulitta O0118Pharmacokinetic/pharmacodynamic evaluation of tigecycline against Klebsiella pneumoniae:higher doses or lower breakpoints needed? L. Amann* (Hamburg, Germany), S.G. Wicha O0119Time-course analysis of the metabolomic footprint of an MDR hypermutable Pseudomonas aeruginosa clinical isolate challenged with ceftolozane/tazobactam in a hollow-fibre infection model J.R. Tait* (Parkville, Australia), D. Anderson, K.E. Rogers, Y. Lang, W.L. Lee, J. Zhou, J.B. Bulitta, R.L. Nation, D.J. Creek, C.B. Landersdorfer O0120A translational rat model utilising iohexol to assess kidney function changes with the addition of piperacillin-tazobactam to vancomycin J. Chang* (Downers Grove, United States), G. Pais, S. Marianski, K. Valdez, E. Barreto, M. Scheetz O0121Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in a mouse bacteraemiamodel S.C. Nang* (Melbourne, Australia), Y.W. Lin, P. Hanafin, J. Wang, K. Chen, H.H. Yu, H. Wickremasinghe, P.J. Bergen, R.Y.K. Chang, G. Rao, K. Chan, J. Li OF02611:00 - 12:00Hall N 1-Hour Mini-oral Flash Session Treatment of XDR bacteria: highway to hell ChairsAmel Letaief (Sousse, Tunisia) Juan P. Horcajada (Barcelona, Spain) O0122Evaluation of the ceftazidime/avibactam for treatment of carbapenem resistant Enterobacteriaceae with OXA-48 and/or NDM genes with or without a combination therapy H. Alqahtani* (Riyadh, Saudi Arabia), A. Alghamdi, A. Alfayez, R. Almousa, N. Alobaidallah, R. Albagli, N. Shamas, F. Farahat, E. Mahmoud O0123Effect of fosfomycin addition to ceftazidime/ avibactam on 30-day mortality in patients with bloodstream infections caused by KPC producing Klebsiella pneumoniae: preliminary results from a retrospective case-control study A. Oliva* (Rome, Italy), L. Volpicelli, S. Di Bari, A. Curtolo, F. Cogliati-Dezza, M. Venditti O0124Ceftazidime-avibactam plus aztreonam for the treatment of metallo- β -lactamase producing Gram-negative bacterial infections A. Sempere* (Barcelona, Spain), B. Viñado, I. Los- Arcos, D. Campany, N. Larrosa, N. Fernández- Hidalgo, D. Rodríguez-Pardo, J.J. González-López, B. Almirante, L. Escolà-VergéSCIENTIFIC PROGRAMME72 Saturday, 23 April 2022 O0125Aminoglycoside resistance in patients colonised with extended-spectrum beta-lactamase (ESBL)- producing Enterobacterales: a retrospective cohort study I. Vock* (Basel, Switzerland), L. Aguilar Bultet, A. Egli, S. Tschudin-Sutter O0126Short- versus long-course antibiotic treatment for vancomycin-resistant enterococcal bacteraemia without a deep-seated focus: a retrospective multi-centre cohort study C. Bahrs* (Jena, Germany), S.R. Rieg, A. Hennigs, F. Hitzenbichler, T. Rolling, R.J. Jacobi, V. Heine, D. Hornuß, S. Hagel, F. Hanses O0127Acidic urine pH worsens clinical outcomes of Escherichia coli bacteriurias S. Fontserè Recuenco* (Seville, Spain), A. Suarez- Benjumea, C. González-Corvillo, C. Infante- Domínguez, S. Herrera-Espejo, Á. Rodríguez- Villodres, J. Pachón, G. Bernal Blanco, M.E. Pachón- Ibáñez, E. Cordero O0128Efficacy of melittin as adjuvant to antibiotics against carbapenemases-producing Gram- negative bacilli S. Herrera Espejo* (Seville, Spain), T. Cebrero Cangueiro, A.B. Guisado Gil, J.A. Cerrillo Matilla, J. Pachón, M.E. Pachón Ibáñez O0129Activity and resistance genomics of cefiderocol and comparators in sequential Pseudomonas aeruginosa isolates from cystic fibrosis patients C. López-Causapé* (Palma, Spain), A. Maruri- Aransol, M.A. Gomis-Font, I. Penev, M. García- Castillo, X. Mulet, J. De Dios Caballero, R. Del Campo, R. Cantón, A. Oliver O0130Synergy between mecillinam and ceftazidime/ avibactam or avibactam against multidrug- resistant carbapenemase-producing Escherichia coli and Klebsiella pneumoniae F.B. Hertz* (Copenhagen, Denmark), K. Knudsen List, M. Kolpen, K. Nørskov Kragh, G. Charbon, S. Radmer, F. Hansen, N. Frimodt-Møller OF02711:00 - 12:00Hall O 1-Hour Mini-oral Flash Session Mechanistic insights into host responses to important pathogens ChairsKate Seib (Brisbane, Australia) Markus Zeitlinger (Vienna, Austria) O0131Staphylococcus aureus biofilm stimulates similar metabolic stress as serum starvation in peripheral blood mononuclear cells resulting in immunosuppressive effects R. Gheitasi* (Jena, Germany), A. Ullah, M. Müller, O. Makarewicz, M. Pletz O0132Helminth infection induces IgE secretion associated with elevated biomarkers of pulmonary destruction in human tuberculosis M. Loader* (London, United Kingdom), S. Vasquez Alves, M. Verastegui, R.H. Gilman, J.S. Friedland O0133Identification of potential vaccine candidate for Paracoccidioides brasiliensis from proteins present in extracellular vesicles by using reverse vaccinology A. Padovan* (Alfenas, Brazil), N.S. Gonçalves O0134Characterisation of the cytosolic innate immune response during Francisella tularensis subsp. holarctica infection L. Ponderand* (Grenoble, France), S. Boisset, T. Henry, G. Gay O0135Impact of bacterial lipoproteins on cytokine activation and immune cell metabolism M.T. Nguyen* (Münster, Germany), H. Schöttler, S. Niemann, M. Mohammad, M. Schultz, T. Jin, H. Hayen, M. Herrmann O0136SFG Rickettsia trigger species-specific alterations in macrophage proteome signatures with different impact in host innate inflammatory responses I. Simões* (Coimbra, Portugal), P. Curto, C. Santa, L. Cortes, B. Manadas O0137Differential activation of IFN receptors in anal cells from HIV+ men during HPV infection M. Scordio* (Rome, Italy), M. Fracella, F. Frasca, L. Sorrentino, G. Oliveto, A. Viscido, L. Santinelli, E.N. Cavallari, G. D’ettorre, P. Gozzo, G. Antonelli, A. Pierangeli, C. Scagnolari O0138Creating a platform to screen immunomodulators to combat respiratory virus immunopathology: the importance of mouse strain selection for therapeutic screening S. Kimber* (Portishead, United Kingdom), C. Cumper, H.S. Lam, M. Miller, K. James, L. Sueiro Ballesteros, C. Kirkham, P. Walters, C. Richards, S.R. Jenkinson O0139Serological response using ELISA anti-VI-IgG after single dose of typhoid conjugate vaccine against Salmonella typhi among children in Hyderabad, Pakistan S. Qureshi* (Karachi, Pakistan), T. Yousafzai, N. Iqbal, A. Hotwani, Z. Khawaja, F. Qamar OF02811:00 - 12:00Hall Q 1-Hour Mini-oral Flash Session COVID-19 treatment insights and advances ChairsRaquel Duarte (Porto, Portugal) Dafna Yahav (Petah-Tikva, Israel) O0140Association of home corticosteroids therapy with COVID-19 disease severity and mortality D.F. Bavaro* (Bari, Italy), F. Balena, E. Pallara, E. De Vita, R. Lattanzio, G. De Iaco, M.F. Mariani, F. Di Gennaro, A. SaracinoFINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202373 Saturday, 23 April 2022 O0141Long-term protease inhibitors in patients living with HIV might prevent COVID-19 infection: aprospective multi-centre cohort study S. Nguala* (Villeneuve-Saint-Georges, France), K. Diallo, A. Belkacem, F. Medina, P. Caraux-Paz, E. Marshal, L. Richier, A. Chahour, S. Diamantis, E. Krastinova, S. Gallien, D. Salmon, N. Vignier, A. Raffetin O0142Development and evaluation of a live biotherapeutic throat spray in COVID-19 primary care patients I. Spacova* (Antwerp, Belgium), I. De Boeck, E. Cauwenberghs, T. Gehrmann, T. Eilers, L. Delanghe, S. Wittouck, T. Henkens, A. Simons, I. Gamgami, L. Persoons, I. Claes, K. Jacobs, K. Loens, D. Schols, S. Coenen, V. Verhoeven, S. Lebeer O0143Effects of inhaled interferon-beta on hospitalised COVID-19 patients receiving supplemental oxygen P. Monk* (Southampton, United Kingdom), V. Tear, J. Brookes, T. Batten, M. Mankowski, F. Gabbay, D. Davies, S. Holgate, R. Djukanovic, T. Wilkinson O0144Long-term benefit of early anakinra treatment in COVID pneumonia at risk: results of the SAVE- MORE trial E. Giamarellos-Bourboulis* (Athens, Greece), A. Kotsaki, S. Metallidis, A. Papailiou, A. Rapti, E. Taddei, G. Boni, M. Gaggadi, Z. Alexiou, F. Saverio Serino, V. Tzavara, K. Dimakou, M. Chini, G. Tsoukalas, C. Selmi, I. Bliziotis, A. Mazgala, K. Akinosoglou, A. Argyraki, S. Sympardi, P. Panagopoulos O0145Benefit and harm of corticosteroids in large population of COVID-19 patients admitted to Spanish intensive care units A. Motos* (Barcelona, Spain), C. Cillóniz, A. Ceccato, L. Fernández-Barat, A. Gabarrús, J. Bermejo, R. Ferrer, J. Riera, O. Peñuelas, J.Á. Lorente, F. Barbé, A. Torres O0146Efficacy and safety of intramuscular administration of AZD7442 (tixagevimab/ cilgavimab) for early outpatient treatment of COVID-19: the TACKLE phase III trial H. Montgomery* (London, United Kingdom), R. Hobbs, F. Padilla, D. Arbetter, A. Templeton, S. Seegobin, K. Kim, J.A. Simon Campos, R. Arends, B. Brodek, D. Brooks, P. Garbes, J. Jimenez, G. Koh, K. Padilla, R. Viani, K. Streicher, V. Alagappan, M. Pangalos, M. Esser O0147Predictive efficacies of bamlanivimab, bamlanivimab/etesevimab, and casirivimab/ imdevimab in treatment of COVID-19 infection A. Gupta* (Antwerp, Belgium), A. Konnova, M. Berkell, V. Van Averbeke, A. Savoldi, M. Morra, M. Mirandola, S. Malhotra Kumar, P. De Nardo, E. Tacconelli, S. Kumar Singh O0148Early administration of remdesivir may reduce mortality in hospitalised COVID-19 patients: a propensity-score matched analysis M. Karolyi* (Vienna, Austria), L. Kaltenegger, E. Pawelka, A. Kuran, M. Platzer, D. Totschnig, F. Koenig, W. Hoepler, H. Laferl, S. Omid, T. Seitz, M. Traugott, S. Arthofer, L. Erlbeck, S. Jaeger, A. Kettenbach, A. Assinger, C. Wenisch, A. Zoufaly VW02911:00 - 12:00Arena 2 Virtual Walk Through Hotchpotch of RTI ModeratorBarbara Rath (Berlin, Germany) ReviewerJordi Carratala (Barcelona, Spain) FO03112:15 - 13:15Arena 1 Open Forum Ethical issues in infectious diseases ChairsTBA F0148ADistribution of vaccines between high- and low-income countries Natasha Anwar (Karachi, Pakistan) F0148BConflict of interest and how to manage it Marco De Ambrogi (London, United Kingdom) F0148CAntibiotic availability gaps in high vs low resource countries TBA F0148DEthical issues in clinical studies during a pandemic: lesson from COVID-19 TBA Co-organised with: ESCMID Ethics Advisory Committee (EEAC) TD03013:00 - 16:00Hall D TAE Day TAE Day ChairsMaiken Arendrup (Copenhagen, Denmark) Emmanuelle Cambau (Paris, France) Önder Ergönül (Istanbul, Turkey) Jon S. Friedland (London, United Kingdom) Angela Huttner (Geneva, Switzerland) Maurizio Sanguinetti (Rome, Italy) Jeroen Schouten (Nijmegen, Netherlands) Luigia Scudeller (Bologna, Italy) Robert Leo Skov (Copenhagen, Denmark) Co-organised with: Trainee Association of ESCMID (TAE) KN03213:30 - 14:30Keynote lectureSCIENTIFIC PROGRAMME74 Saturday, 23 April 2022Saturday, 23 April 2022 ID KN03213:30 - 14:30Hall A Keynote lecture Clinical research in infectious endocarditis: past, present, and future Chairs Winfried Kern (Freiburg, Germany) Annelies Zinkernagel (Zurich, Switzerland) K014913:30 José M. Miro (Barcelona, Spain) Dr. José M. Miró has been Senior Consultant of Infectious Diseases at the Hospital Clinic – IDIBAPS of Barcelona since 2001. He is Professor of Medicine at the University of Barcelona, IDIBAPS investigator and Director of the Master of HIV/AIDS of the University of Barcelona. His research fieldsarefocusedoninfectiveendocarditis(includingthe experimental model) and HIV/AIDS (cohort studies, primary HIV-1 infection, opportunistic Infections, late presenters, solid organ transplantation in HIV-1 infection, COVID-19). He has published more than 850 articles in peer-reviewed journals (h-index 76). He was President of GESIDA (1998- 99), the Catalan Society of Infectious Diseases and Clinical Microbiology (SCMIMC, 2005-07), the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC, 2013- 15) and currently is President of the International Society of Cardiovascular Infectious Diseases (ISCVID, 2019-23). Fireplace Session23 April, 15:00 - 16:00 CM IC SY03313:30 - 15:30Hall C Symposium The dark side of Gram-negative respiratory infections in the ICU ChairsCamilla Rodrigues (Mumbai, India) Harald Seifert (Cologne, Germany) S015013:30The phylogenetic landscape and nosocomial spread of Stenotrophomonas maltophilia Thomas Kohl (Borstel, Germany) S015114:00Factors contributing to the persistence of pathogenic Acinetobacter in the hospital setting Paolo Visca (Rome, Italy) S015214:30The microbiology and pathogenesis of Stenotrophomonas maltophilia infection Joanna Brooke (Chicago, United States) S015315:00How to diagnose and treat infection with non- fermenters in the ICU Adrien Bouglé (Paris, France) CM SY03413:30 - 14:30Hall E Symposium Year in Clinical Microbiology ChairsLuisa Maria Vieira Peixe (Porto, Portugal) Ana Gales (São Paulo, Brazil) S015413:30Brigitte Lamy (Nice, France) S015514:00Veroniek Saegeman (Sint-Niklaas, Belgium) CM SY03513:30 - 14:30Hall G Symposium Exploring the urinary microbiome: facts, figures and therapeutic potential ChairsTomislav Mestrovic (Seattle, United States) Maria Vehreschild (Frankfurt am Main, Germany) S015613:30Mapping the urinary microbiome repertoire TBA S015714:00Harnessing the therapeutic potential of the urinary microbiota Elisabeth Terveer (Leiden, Netherlands) Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) ID SY03613:30 - 15:30Hall J Symposium Making decisions on antibiotic therapy in difficult situations ChairsBojana Beovic (Ljubljana, Slovenia) Francoise Van Bambeke (Brussels, Belgium) S015813:30Streamlining empirical drugs when aetiology is unclear: is it possible? Vera Vlahovic-Palcevski (Rijeka, Croatia) S015914:00Stopping therapy in doubtful situations José Molina Gil-Bermejo (Seville, Spain) S016014:30Avoiding combinations in severe infections and when XDR organisms are involved Felipe Francisco Tuon (Curitiba, Brazil) S016115:00Dosing optimisation in real life: with which drugs, when and how? Birgit Koch (Rotterdam, Netherlands) ID CM EW03713:30 - 15:30Hall I Educational Workshop Getting your CM/ID paper published ChairsAlex Friedrich (Münster, Germany) Ed Kuijper (Leiden, Netherlands) W016213:30Being an author: how to write scientific articles Jesús Rodríguez-Baño (Seville, Spain) W016314:00Being a peer-reviewer: how to perform reviews Mariska Mg Leeflang (Amsterdam, Netherlands)FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202375 Saturday, 23 April 2022Saturday, 23 April 2022 W016414:30The Editor’s view Leonard Leibovici (Petah-Tiqva, Israel) Co-organised with: CMI Board of Editors OS03813:30 - 14:30Hall F 1-Hour Oral Session Clinical aspects of HIV infection ChairsSiri Goepel (Tübingen, Germany) Milosz Parczewski (Szczecin, Poland) O0165Risk of subarachnoid haemorrhages and aneurysms in Danish people living with HIV: a nationwide cohort study M. Tetens* (Copenhagen, Denmark), J. Gerstoft, G. Kronborg, I.S. Johansen, C.S. Larsen, L. Weise, M. Dalager-Pedersen, L.H. Omland, N. Obel O0166Changing landscape of liver transplantation in post-direct acting antivirals and contemporary highly effective antiretroviral era H. Saeed* (Rochester, United States), E. Cano, N. Cummins, Z. Yetmar, M. Leise O0167Prevalence of transmitted drug resistance among late presenters in Europe M.N.S. Miranda* (Lisbon, Portugal), M. Pingarilho, V. Pimentel, M.D.R. O. Martins, R. Kaiser, C. Seguin- Devaux, R. Paredes, M. Zazzi, F. Incardona, A. Abecasis O0168PrEP scale-up and PEP in central and eastern Europe: what has changed and what challenges we face? J. Kowalska* (Warsaw, Poland), D. Gokengin, D. Bursa, A. Skrzat-Klapaczynska, I. Alexiev, J. Begovac, A. Cicic, G. Dragovic, A. Harxhi, K. Kase, B. Lakatos, R. Matulionyte, V. Mulabdic, C. Oprea, A. Papadopoulos, N. Rukhadze, D. Sedlacek, J. Tomazic, A. Vassilenko, M. Vasylyev, A. Verhaz, N. Yancheva, O. Yurin O0169STI incidence and risk factors for infection and reinfection after introduction of a systematic screening programme for men having sex with men: a longitudinal study in a HIV Cohort P. Mathé* (Freiburg, Germany), S. Usadel, S. Rieg, W. Kern, M. Müller OS03913:30 - 14:30Hall H 1-Hour Oral Session New mechanisms of antifungal resistance in emerging yeast pathogens ChairsDominique Sanglard (Lausanne, Switzerland) Cornelia Lass-Flörl (Innsbruck, Austria) O0170A novel Candida aurissingle nucleotide gene editing system reveals the direct impact of mutations inFKS1on echinocandin resistance J. Rybak* (Memphis, United States) O0171Combining genomic and proteomic data to elucidate 5-fluorocytosine resistance in Cryptococcus neoformans species F.Z. Delma* (Nijmegen, Netherlands), J.P.M. Coolen, A. Cabrera-Orefice, A.M.S. Al-Hatmi, W.J.G. Melchers, S. De Hoog, P.E. Verweij, J.B. Buil O0172Azole-resistant Candida parapsilosis: a new challenge M. Cabrera* (Madrid, Spain), I. Sánchez, M. Muñoz, A. Pérez, J. Guinea, Ó. Zaragoza, J. Díaz- García, A. Ramos, A. Fernández, F. Portero O0173Fluconazole-induced microevolution of Candida parapsilosisharbouring novel mutation G490R in Tac1p: a new site responsible forazole- resistance and virulence abatement N. Yating* (Beijing, China), Y.T. Ning, T.S. Sun, L. Zhang, Y.C. Xu O0174Role of the Candida glabrata mediator complex subunit CgPgd1 in azole drug resistance and susceptibility: a transcriptomics approach M. Galocha* (Lisbon, Portugal), R. Viana, I. Costa, P. Pais, M. Cacho Teixeira OS04013:30 - 14:30Hall K 1-Hour Oral Session Ever challenging malaria ChairsSipho Kenneth Dlamini (Observatory, South Africa) Anu Kantele (Helsinki, Finland) O0175The role of host and parasite biomarkers in the diagnosis of severe imported Plasmodium falciparum malaria L. Balerdi-Sarasola* (Barcelona, Spain), C. Parolo, C. Angie, S. Carme, N. Rodriguez-Valero, A. Almuedo- Riera, L. Letona, M. Alfredo, M.J. Álvarez-Martínez, M.E. Valls, A. Cristian, F. Rosario, M. Jose, C. Daniel O0176Amplicon deep sequencing using commercial technology to study drug-resistant Plasmodium vivax C. Kamaliddin* (Calgary, Canada), L. Fine, D. Castaneda Mogollon, D.R. Pillai O0177Effects of ivermectin mass drug administration for malaria vector control on ectoparasites and soil-transmitted helminths C. Kositz* (London, United Kingdom), M. Drammeh, H. Vasileva, J. Houghton, E. Dabira, U. D’ Alessandro, M. Marks, J. Bradley O0178Prevalence of glucose-6-phosphate dehydrogenase deficiency (G6PDd), commercial qualitative rapid diagnostic test performance, and genetic variants in two malaria-endemic areas in Sudan M. Albsheer* (Khartoum, Sudan), A. Lover, A. Mohamad, M. Abdel HamidSCIENTIFIC PROGRAMME76 Saturday, 23 April 2022 O0179Prevalence of malaria and anaemia, knowledge and practices of malaria preventive methods among pregnant women attending Vanga hospital at first antenatal care visit, Democratic Republic of the Congo J. Mudji E’kitiak* (Vanga, Congo, the Democratic Republic of the), B. Madinga, P. Kabamba, V. Olubunmi OS04113:30 - 14:30Hall M 1-Hour Oral Session Novel approaches to antimicrobial susceptibility testing ChairsAna Gales (São Paulo, Brazil) Marek Gniadkowski (Warsaw, Poland) O0180Pilot two-site study of a simple, smartphone compatible miniaturised broth microdilution test with Gram-negative uropathogens S. Needs* (Reading, United Kingdom), P. Lumbreras-Iglesias, J. Fernández, A. Edwards O0181Artificial intelligence (AI)-assisted antimicrobial susceptibility testing (AST): automated imaging and the use of artificial intelligence for interpretation of disc-diffusion AST according to EUCAST, including rapid antimicrobial susceptibility testing (RAST) H. Wisplinghoff* (Cologne, Germany), N. Jazmati, A. Nowag, L. Radder, C. Bernsen, R. Hill, S. Giglio O0182Comparative analysis of population analysis profiling approaches to identify colistin heteroresistance in Klebsiella pneumoniae S.G. Rajakani* (Antwerp, Belgium), B.B. Xavier, A.A. Sey, M. Elbounja, C. Lammens, H. Goossens, S. Malhotra-Kumar O0183Individual antimicrobial killing profilesreveal clinical outcomes F. Bright* (Basel, Switzerland), A. Jovanovic, B. Wicki, L. Sauteur, A. Wuest, D.M. Grogono, F. Geier, M. Tamm, P. Dehio, J. Nemeth, M. Abanto, R. Thomson, S. Bell, A.R. Floto, L. Boeck O0184Haemin-dependent metronidazole resistance in epidemic Clostridoides difficile J. Freeman* (Leeds, United Kingdom), W. Spittal, C. Chilton, M. Wilcox, J. Hurdle VW04213:30 - 14:30Arena 2 Virtual Walk Through Under the hood: mechanisms of action of new antibacterial agents ModeratorUrsula Theuretzbacher (Vienna, Austria) ReviewerBanu Bayraktar (Istanbul, Turkey) CM KN04314:45 - 15:45Hall A Keynote lecture Pathogens and the microbiome: antibiotics at the crossroads Chairs Kimberly Kline (Singapore, Singapore) Christian Giske (Stockholm, Sweden) K018514:45 Martin Blaser (New Jersey, United States) Martin J. Blaser holds the Henry Rutgers Chair of the Human Microbiome at Rutgers University, New Brunswick, United States, and serves as director of the Center for Advanced Biotechnology and Medicine. Previously, he served as chair of the Department of Medicine at New York University. A physician and microbiologist, Dr. Blaser has been studying the relationships we have with the human microbiome, the bacteria that live in us. Over the last 20 years, he has also been actively studying the relationship of the human microbiome with both health and important diseases including asthma, obesity, diabetes, and cancer. Dr. Blaser has been the advisor to many students, post-doctoral fellows, and faculty. He has served as president of the Infectious Diseases Society of America,ChairoftheBoardofScientificCounselorsofthe National Cancer Institute, and Chair of the Advisory Board for Clinical Research of the NIH. He currently serves as chair of the Presidential Advisory Council for Combatting Antibiotic Resistant Bacteria (PACCARB). He was elected to the National Academy of Medicine and the American Academy for Arts and Sciences.Hehasauthoredover630originalscientificarticles, and holds 24 U.S. patents, and he also wrote Missing Microbes, a book targeted to general audiences, now translated into 20 languages. Co-organised with: ESCMID Study Group for Host and Microbiota Interaction (ESGHAMI) and American Society of Microbiology (ASM) Fireplace Session23 April, 16:15 - 17:15 ID PH SY04414:45 - 15:45Hall E Symposium Respiratory viral infections in hospital settings ChairsDaniele Roberto Giacobbe (Genoa, Italy) Chrysanthi Skevaki (Marburg, Germany) S018614:45Respiratory virus infections in ICU patients besides SARS-CoV-2: what matters? Charles-Edouard Luyt (Paris, France) S018715:15Guidelines for diagnosis of COVID-19 and influenza Barbara Rath (Berlin, Germany) Co-organised with: ESCMID Study Group for Respiratory viruses (ESGREV), ESCMID Study Group for Infections in Critically Ill Patients (ESGCIP)FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202377 Saturday, 23 April 2022 SY04514:45 - 15:45Hall F Symposium One Health and mycology: what are the significant and potential interactions between agriculture and human health? ChairsJustin Beardsley (Sydney, Australia) Cornelia Lass-Flörl (Innsbruck, Austria) S018814:45What is the evidence that agricultural azole use drives drug resistance in human fungal pathogens? Paul Eduard Verweij (Nijmegen, Netherlands) S018915:15How can we minimise the risk of development of antifungal resistance in the environment? Marin Brewer (Watkinsville, United States) ID SY04614:45 - 15:45Hall G Symposium Should you manage bloodstream infection differently in immunocompromised patients? ChairsJose Maria Aguado Garcia (Madrid, Spain) Maddalena Giannella (Bologna, Italy) S019014:45Rapid diagnostic testing: is it a life saver for immunocompromised patients? Gian Maria Rossolini (Florence, Italy) S019115:15What is different in the treatment of immunocompromised patients Maristela P. Freire (São Paulo, Brazil) Co-organised with: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) OS04714:45 - 15:45Hall B 1-Hour Oral Session A post-COVID syndrome: a never-ending story ChairsCristiana Oprea (Bucharest, Romania) Sotirios Tsiodras (Athens, Greece) O0192Vagus nerve dysfunction in post-COVID-19 condition G. Lladós* (Badalona, Spain), M. Massanella, R. Coll, R. Rodriguez, E. Hernandez, G. Lucente, A. Martinez-Piñeiro, S. España, J.R. Santos, C. Lopez, C. Loste, M.J. Dominguez, I. Casafont, C. Bracke, R. Paredes, L. Mateu O0193SARS-CoV-2 variants may induce different long COVID phenotypes M. Spinicci* (Florence, Italy), J. Nkurunziza, I. Vellere, L. Graziani, M. Tilli, B. Borchi, J. Mencarini, I. Campolmi, L. Giovannoni, L. Rasero, F. Fattirolli, I. Olivotto, F. Lavorini, N. Marchionni, L. Zammarchi, A. Bartoloni O0194Gut microbiome profiles in type 2 diabetes patients after COVID-19 G. Pircalabioru* (Bucharest, Romania), G. Gradisteanu, M.C. Chifiriuc, O. Savu, M. Popa, L. Marutescu O0195Insomnia among recovered COVID-19 individuals H.T. Hashim* (Nassiryah, Iraq), M.A. Ramadhan O0196Factors associated with self-reported post-acute COVID-19 syndrome: a real-world data study A. Thronicke* (Berlin, Germany), M. Hinse, S. Weinert, A. Jakubowski, F. Schad, H. Matthes OS04814:45 - 15:45Hall K 1-Hour Oral Session Modelling host-pathogen interaction in persistent infections ChairsLuisa Martinez-Pomares (Nottingham, United Kingdom) Gordon Ramage (Glasgow, United Kingdom) O0197Antibiotic treatments can indirectly affect the expression of Pseudomonas aeruginosa virulence determinants in vitro models: a pilot study S. Renica* (Milan, Italy), F. Magaraggia, R. Scutari, M. Antonello, C. Vismara, A. Pani, C. Alteri, F. Scaglione O0198Ecological interactions in cystic fibrosis- associated pathogens alter antibiotic sensitivity of Pseudomonas aeruginosa C. Koumans* (Leiden, Netherlands), A. Liakopoulos, J.G.C. Van Hasselt O0199In vitropolymicrobial wound biofilm model systems for assessing antimicrobial treatment efficacy and host-pathogen interactions J. Brown* (Glasgow, United Kingdom), E. Townsend, R. Short, C. Williams, C. Woodall, C. Nile, G. Ramage O0200Modelling host-pathogen interactions in the context of chronic wounds K. Lee* (Nottingham, United Kingdom), D. Jackson, M. Camara, L. Martinez-Pomares O0201Standardised methods to rear high-quality Galleria mellonella larvae for the study of fungal pathogens A. De Jong* (Utrecht, Netherlands), D. Van Veldhuizen, A. Groot, F. Hagen OF04914:45 - 15:45Hall H 1-Hour Mini-oral Flash Session Targets for antimicrobial stewardship ChairsHelen Giamarellou (Athens, Greece) Lior Nesher (Be'er Sheva, Israel) O0202Identifying clinical scenarios in which POCT is most likely to improve antimicrobial stewardship in ICU: a behavioural study from the “Why Stop” collaborative S. Mason* (London, United Kingdom), M. Nurek, M. Vizcaychipi, S. SinghSCIENTIFIC PROGRAMME78 Saturday, 23 April 2022 O0203Trends of antimicrobial use through ECDC antimicrobial indicators in Spain, 2012-21 M. Cantero Caballero* (Majadahonda, Spain), E. Jiménez Tejero, L.M. Parra Ramírez, Á. Asensio Vegas, R.M. Orti Bordas, I. Salcedo Leal O0204Long-term antibiotic prescribing in the community: six-years of Australian national data A. Macphail* (Melbourne, Australia), T. Korman, I. Woolley, J. Lau O0205National action plans for antimicrobial resistance: a framework for operationalising existing plans and developing a research strategy to address gaps and opportunities E. Charani* (London, United Kingdom), M. Mendelson, R. Ahmad, M. Mpundu, O. Mbamalu, C. Bonaconsa, S. Singh, N. Peiffer-Smadja, S. Pallett, V. Anton Vazquez, L. Moore, J. Schouten, T. Kostyanev, V. Vlahovic-Palcevski, D. Kofteridis, A. Holmes O0206Identifying relevant targets for antimicrobial stewardship: appropriateness of surgical prophylaxis in paediatric surgery A.M. Colombari* (Verona, Italy), E. Rigotti, E. Carrara, F. Opri, M. Sibani, M. Gaffuri, F. Sala, G.B. Luciani, F.L. Ribichini, B. Magnan, M. Balsano, M. Carlucci, E. Tacconelli, G. Piacentini O0207Exploring the case for a standardised physical appearance of oral generic antibiotics: a summary of expert roundtable meetings A. Monnier* (Nijmegen, Netherlands), T. Sharmeen, N.T. Do, S. Afari-Asiedu, K.P. Asante, M.A. Abdulai, W.A. Khan, M.A. Matin, K. Munguambe, H. Boene, E. Sevene, N. Torres, S. Punpueng, M. Sunpuwan, T.K. Tran, C.T.K. Nguyen, X. Gómez-Olivé, P.N. Newton, C. Caillet, K. Van Assche, H.R. Van Doorn, P. Ariana, H.F.L. Wertheim O0208Development of national indicators for the antimicrobial stewardship in French nursing homes based on reimbursement data: results from a modified delphi process G. Birgand* (Nantes, France), A. Asquier-Khati, C. Deschanvres, A. Chaslerie, O. Pereira, C. Pulcini, D. Boutoille O0209Variability in antimicrobial consumption among nursing homes and the impacts of length of stay and preceding acute care stay: a nationwide cohort study at the US veterans health administration M. Goto* (Iowa City, United States), S. Kakiuchi, D. Livorsi, D. Perencevich, M. Ohl O0210Alterative antimicrobial stewardship interventions can impact breath of spectrum but not volume of antibacterials in UK emergency departments: an analysis of two London teaching hospitals over 5 years S. Hughes* (London, United Kingdom), O. Troise, P. Deol, N. Mughal, L. Moore VW05014:45 - 15:45Arena 1 Virtual Walk Through Wise use of bioinformatics to study diversity and transmission in endemic and outbreak settings ReviewerAnita Schürch (Utrecht, Netherlands) ModeratorHelena Seth-Smith (Basel, Switzerland) ID SY05116:15 - 18:15Hall E Symposium Molecular-guided therapy for sexually transmitted infections ChairsMichael Beeton (Cardiff, United Kingdom) Titia M. Kortbeek (Bilthoven, Netherlands) S021116:15Molecular-guided therapy for Mycoplasma genitalium Catriona Bradshaw (Carlton, Australia) S021216:45Molecular-guided therapy for gonorrhea Magnus Unemo (Örebro, Sweden) S021317:15Molecular-guided therapy for Chlamydia trachomatis Cecile Bebear (Bordeaux, France) S021417:45STIs in a sexual assault: sampling guidelines Amparo Fernández-Rodríguez (Madrid, Spain) Co-organised with: ESCMID Study Group for Genomic and Molecular Diagnostics (ESGMD), ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGAMC), ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR), Study Group of Sexually Transmitted Diseases of the SEIMC (GEITS) PH EW05216:15 - 18:15Hall B Educational Workshop COVID-19 vaccination of special populations: protecting the vulnerable ChairsOlivier Epaulard (Grenoble, France) Zitta Barrella Harboe (Hillerød, Denmark) W021516:15Vaccinating immunocompromised individuals Aruna Subramanian (Stanford, United States) W021616:45Vaccinating individuals with underlying medical conditions associated with high risk for severe COVID-19 TBA W021717:15Vaccination of infants and children, and of pregnant women Christoph Berger (Zurich, Switzerland) Co-organised with: ESCMID Study Group on Vaccines (EVASG), ESCMID Professional Affairs Subcommittee (PAS), ESCMID International Affairs Subcommittee (EIAS)FINAL PROGRAMME – 33RD ECCMID Copenhagen, Denmark 202379 Saturday, 23 April 2022 ID EW05316:15 - 18:15Hall F Educational Workshop Opportunistic infections of the central nervous system ChairsBettina Pfausler (Innsbruck, Austria) Willeke Westendorp (Amsterdam, Netherlands) W021816:15Suspecting CNS infection in haemato-oncology patients Jacob Bodilsen (Aalborg, Denmark) W021916:45Infections of the CNS in solid organ transplant patients Judith Anesi (Philadelphia, United States) W022017:15Fungal CNS infections in immunocompromised patients Stefan Schwartz (Berlin, Germany) Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain (ESGIB) ID EW05416:15 - 18:15Hall I Educational Workshop What is new in nocardiosis? ChairsMaría Ercibengoa Arana (San Sebastian, Spain) Mehdi Fatahi-Bafghi (Yazd, Iran, Islamic Republic of) W022116:15Challenges in susceptibility testing of Nocardia Barbara Brown-Elliott (Tyler, United States) W022216:45Risk factors among susceptible populations: is there a role for prophylaxis? David Lebeaux (Paris, France) W022317:15Tailor-made treatment regimens for nocardiosis: can imaging and other clinical markers guide therapeutic decision making? Ili Margalit (Petah Tikva, Israel) ID CM EW05516:15 - 18:15Hall K Educational Workshop Should economical aspects be considered for CM/ID/ICP guidelines? ChairsChantal Morel (Bonn, Germany) Luigia Scudeller (Bologna, Italy) W022416:15The current state of inclusion of economic issues in infectious disease guidelines Ravi Jhaveri (Chicago, United States) W022516:45Pro (considering economic aspects for guideline development) Joost Hopman (Nijmegen, Netherlands) W022617:15Con (considering economic aspects for guideline development) Benedikt Huttner (Geneva, Switzerland) Co-organised with: ESCMID Guidelines Subcommittee (GL-SC) CM EW05616:15 - 18:15Hall N Educational Workshop The quest for reliable biofilm models: how to narrow the gap to clinical implementation? ChairsElisa Borghi (Milan, Italy) Gordon Ramage (Glasgow, United Kingdom) W022716:15Real-time monitoring of biofilms using confocal microscopy Mathias Müsken (Braunschweig, Germany) W022816:45Bacterial infection models based on organoid cell cultures Helle Krogh Johansen (Copenhagen, Denmark) W022917:15In vivo models: studying soft tissue infection Kendra P. Rumbaugh (Lubbock, United States) Co-organised with: ESCMID Study Group for Biofilms (ESGB) OS05716:15 - 18:15Hall C 2-Hour Oral Session Digging in the molecular epidemiology of MDR Enterobacterales ChairsLorena Lopez Cerero (Seville, Spain) Dror Marchaim (Beer Yaacov, Israel) O0230Expansion of Enterobacterales producing VIM- type carbapenemases in Poland, 2006-19: general analysis R. Izdebski* (Warsaw, Poland), M. Biedrzycka, P. Urbanowicz, D. Zabicka, E. Literacka, M. Gniadkowski O0231Dissemination of carbapenemase producing Enterobacterales in Ireland from 2012- 2017: a retrospective genomic surveillance study N.F. Hadjirin* (Cambridge, United Kingdom), A.J. Van Tonder, J.A. Lees, N. Kumar, N. Delappe, W. Brennan, E. Mcgrath, J. Parkhill, M. Cormican, S.J. Peacock, C. Ludden O0232Klebsiella variicola population structure and antibiotic resistance J. Wang* (Edinburgh, United Kingdom), C. Swart- Coipan, E. Wessels, E. Feil, E. Franz, T. Dorai- Schneiders O0233A genetic cluster of OXA-244 carbapenemase- producing Escherichia coliST38 with uropathogenicity factors in the Netherlands D.W. Notermans* (Bilthoven, Netherlands), A.F. Schoffelen, F. Landman, L.H. Wielders, S. Witteveen, M. Van Santen-Verheuvel, S.C. De Greeff, E. Kuijper, A.P.A. Hendrickx O0234Multispecies carriage of KPC-2: an outbreak centred on the mobilome K. Xanthopoulou* (Cologne, Germany), J. Wille, V. Persy, T. Burgwinkel, K. Lucaßen, J. Zweigner, A. Meißner, H. Seifert, P.G. HigginsNext >